Bristol's Taxol Appeal Emphasizes Contribution Of Improved Dosing Regimen
Executive Summary
Bristol-Myers Squibb's Taxol patent appeal hinges in part on the company's arguments that it should receive a reward for bringing an improved dosing schedule for paclitaxel to the public.